This clinical trial is focused on studying the treatment of idiopathic male infertility, which is a condition where men experience unexplained difficulties in conceiving a child due to reduced semen quality. The trial will evaluate the effectiveness and safety of a medication called follitropin delta, marketed under the name REKOVELLE. This medication is administered as a solution for injection using a pre-filled pen. The study will compare the effects of follitropin delta with a placebo, which is an inactive treatment, to determine its impact on the chances of achieving a spontaneous pregnancy in the female partners of the participants.

The purpose of the study is to investigate whether follitropin delta can improve the likelihood of spontaneous pregnancy in couples where the male partner has idiopathic infertility. Participants in the study will receive either the active medication or a placebo. The study will be conducted over a period of several months, during which the participants will be monitored for any changes in their condition and the occurrence of pregnancy in their partners. The trial aims to provide valuable insights into the potential benefits of follitropin delta for men with this type of infertility.

Throughout the study, participants will receive regular follow-ups to assess their response to the treatment and to ensure their safety. The main goal is to observe whether the use of follitropin delta leads to a higher rate of spontaneous pregnancies compared to the placebo. This research could offer new hope for couples struggling with unexplained infertility by potentially providing an effective treatment option for improving fertility outcomes.